HES1 overexpression
|
HCC
|
HES1 overexpression
|
HCC
|
bevacizumab + atezolizumab Resistant: C3 – Early Trials
|
bevacizumab + atezolizumab Resistant: C3 – Early Trials
|
HES1 overexpression
|
Mantle Cell Lymphoma
|
HES1 overexpression
|
Mantle Cell Lymphoma
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|
rituximab + ibrutinib Sensitive: C3 – Early Trials
|